Inhibitors in haemophilia A: a perspective on clotting factor products as a potential contributing factor
نویسندگان
چکیده
منابع مشابه
Driving patterns as a contributing factor to light-duty vehicular emission in the Kumasi metropolis
Exhaust emissions contribute greatly to air pollution, the social cost of which may occur as danger to human health, attracting huge medical expenses, causing absenteeism and hence loss of productivity. These are incentives to reduce exhaust emissions to the barest minimum. Two major cities in Ghana, Accra and Kumasi, are struck by vehicular traffic jams especially during rush-hours and are gra...
متن کاملDriving patterns as a contributing factor to light-duty vehicular emission in the Kumasi metropolis
Exhaust emissions contribute greatly to air pollution, the social cost of which may occur as danger to human health, attracting huge medical expenses, causing absenteeism and hence loss of productivity. These are incentives to reduce exhaust emissions to the barest minimum. Two major cities in Ghana, Accra and Kumasi, are struck by vehicular traffic jams especially during rush-hours and are gra...
متن کاملDetection of Factor VIII Inhibitors in Hemophilia A Patients
Background: Factor VIII administration to hemophilia A patients results in an immune response (inhibitor formation) which significantly complicates the therapy. The present study was performed to determine the prevalence of inhibitor development in hemophilia A patients receiving recombinant factor VIII therapy. Materials and Methods: This was an observational descriptive study. Clotting fac...
متن کاملAlcohol as a potential contributing factor in radiation complications.
Various predisposing situations or conditions have been associated with a heightened risk of serious complications following therapeutic irradiation (XRT). Some examples include diabetes,1 ataxia telangiectasia,2 collagen vascular diseases such as scleroderma, lupus, or CREST syndrome (calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia),3,4 or prior abdomi...
متن کاملFactor VIII products in haemophilia A: one size fits all?
The development of alloantibodies (inhibitors) that inactivate the coagulant activity of factor VIII (FVIII) is the major problem for the management of persons with severe haemophilia A (1). This complication occurs in approximately one third of boys previously untreated and hence first exposed to FVIII-containing products (2, 3). The risk of inhibitors is maximal during the first 20 treatments...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Haemophilia
سال: 2016
ISSN: 1351-8216,1365-2516
DOI: 10.1111/hae.12888